Since mesothelioma is often difficult to treat, scientists and researchers look to combination treatments and therapies to improve chances of patients’ survival. There is no “one” treatment that is used across the board in treating mesothelioma, because patients react differently, whether it is to chemotherapy, radiation therapy, immunotherapy, or surgery. A research team from MD
Archive for the 'Novel Treatments & Drugs' Category
Rare and aggressive in nature, mesothelioma is often a fatal cancer mainly due to its lack of response to most treatments. Surgical options have a higher chance of success for those in the early stages of the disease, but since there is a long latency period between asbestos exposure and symptoms of mesothelioma, often times
Tremelimumab Earlier in the spring of 2017, scientists and researchers from the University of Salford in the UK published a special report questioning the effectiveness of the new immunotherapy treatment known as tremelimumab. Trials of the check point inhibitor did not show promising results and there was concern about the drug’s effectiveness, safety, and tolerability.
When it comes to different treatments for mesothelioma patients, there is no shortage of diversity, as options include chemotherapy, radiation, surgery, immune-based therapies, gene-based therapies, and more. Chemotherapy treatments cisplatin and pemetrexed are first line treatments, especially among those who do not quality for surgery. Radiation treatment is available, but is typically the path less
Known as a bisphosphonate, zoledronic acid is typically used for bone diseases such as osteoporosis, and to treat high calcium levels in the blood that can lead to other health complications. Nitrogen containing bisphosphonates like zoledronic acid are known to have cancer suppressing qualities, and scientists and researchers were eager to find out if zoledronic
A Phase I study for cediranib, a VEGFR/PDGFR kinase inhibitor, showed promising results in shrinking tumor size and increasing survival rates for those suffering from malignant pleural mesothelioma. This is not the first time cediranib has been studied as a possible treatment for mesothelioma. In 2011/2012 a Phase II trial for cediranib conducted by researchers
Mesothelioma is a rare and aggressive cancer that is difficult to diagnose because symptoms often mimic other diseases such as pulmonary fibrosis or lung cancer. Pathology reports and biopsies help distinguish this cancer from other illnesses, but often patients will have already developed more serious symptoms because the cancer has spread by the time it
A biopharmaceutical company named Aduro Biotech recently announced its collaboration with Merck to further evaluate the findings for the Phase II trial of KEYTRUDA ® (pembrolizumab) and to combine their own immunotherapy treatment, CRS-207. Information regarding KEYRUDA ® treatment began to circulate late last year when data presented at the 17th World Conference on Lung
The results of a 2016 Phase III trial of the monoclonal antibody bevacizumab (Avastin) have established another option for treatment for those suffering from malignant pleural mesothelioma. Angiogenesis, which is the formation of new blood vessels, plays a key role in mesothelioma because it allows the tumors and cancer to spread. However, scientists and researchers
The latest success concerning a treatment for non- small cell lung cancer (NSCLC) has scientists and researchers hopeful that the same treatment can be applied to mesothelioma victims. The Phase III trial for Alecensa (alectinib), while currently not recruiting participants, is on-going and results thus far have shown to be promising for those with NSCLC.
The latest findings in cancer treatments for the often fatal mesothelioma have scientists and researchers hopeful that they are one step closer in finding a consistent, effective treatment for the asbestos-caused cancer. The LUME-Meso Phase II trial for patients with malignant pleural mesothelioma focused on the administration of the triple angiokinase inhibitor called Nintedanib. This oral
Mesothelioma’s aggressive nature makes it difficult to treat with common cancer treatments such as chemotherapy and radiation. Scientists and researchers are constantly looking for new ways to treat mesothelioma outside of chemotherapy and radiation, such as gene therapy or immunotherapy. Immunotherapy is a novel approach and sometimes a more viable option for those suffering from
Scientists and researchers are excited over the latest completion of a Phase II clinical trial for those suffering from mesothelioma – an incurable asbestos-caused cancer that has a median survival of only 9 to 12 months. The LUME-Meso Phase II trial for patients with malignant pleural mesothelioma showed a slight increase in progression-free and overall
Mesothelioma is an incredibly difficult cancer to treat. Its late stage diagnosis coupled with its aggressive nature leaves victims without very much time to combat this fatal cancer. There are a variety of treatment options available to those suffering from mesothelioma, even though there is no cure. Surgery Radiation Chemotherapy Intraoperative photodynamic therapy Immunotherapy Gene
Those suffering from mesothelioma know that the prognosis is grim. The average life expectancy for someone who is recently diagnosed is only eight months. Chemotherapy is the standard treatment for mesothelioma, but in most cases, the cancer is too far advanced for chemotherapy to be effective. Surgery for mesothelioma is possible but results from surgery
Last update: March 06, 2014. 08:41:31 pm.